Lung cancer is the third leading cause of worldwide incidence of neoplastic diseases, and the leading cause of death from this disease. Inflammation is known to play a vital role in the spread of cancer cells. The aim of this work was to evaluate whether inflammatory indices determined by neutrophil/lymphocyte and platelet/lymphocyte ratios in lung cancer patients have a prognostic value for survival and/or predictive of the effect of immunotherapy treatments with CIMAvac-EGF, CIMAher (nimotuzumab) and VAXIRA (racotumomab). For this purpose, the levels of neutrophils, platelets and lymphocytes were measured after diagnosis, the ratios between the different cells were calculated and overall survival was estimated using the Kaplan Meier method. Likewise, the cut-off points where the difference between the different groups was greater were found, in order to establish whether the inflammatory indices studied were predictors or prognostic of survival. The results of the present investigation showed that low inflammatory indexes are good predictors of long survival and good prognosis.